Treating Schizophrenia: Milestone Results Released By This Company
Reviva Announces Groundbreaking Phase 3 Results for Schizophrenia Drug Brilaroxazine.
In a significant breakthrough for the world of mental health, Reviva Pharmaceuticals Holdings Inc. has released positive topline results from its global pivotal Phase 3 RECOVER trial of Brilaroxazine in treating schizophrenia. This news is set to change the narrative around schizophrenia treatment and bring new hope to millions suffering from this debil…